Oral Administration of N-Acetyl-seryl-aspartyl-lysyl-proline Ameliorates Kidney Disease in Both Type 1 and Type 2 Diabetic Mice via a Therapeutic Regimen

Figure 2

Change in the levels of AcSDKP after oral administration of AcSDKP in diabetic mice. ((a)-(b)) STZ-induced type 1 diabetic mice were treated with imidapril at 16 weeks after the diabetic induction. At 20 weeks after the induction of diabetes, some imidapril-treated mice were given 1 mg of AcSDKP by oral gavage 3 times per week. Urine was harvested just before, after 2 and 24 hours after the final administration of AcSDKP. (a) Time course, (b) area under the curve. in each group. ((c)-(d)) At 20 weeks of age, diabetic db/db mice were divided into 4 groups (no treatment, imidapril, AcSDKP oral, and imidapril + AcSDKP combination). 1 mg of AcSDKP was given by oral gavage 3 times per week. Urine samples were harvested at before, 2 hours, 24 hours, and 48 hours (same as at euthanasia) after the final administration of AcSDKP. (c) Time course, (d) area under the curve. or 6 in each group were analyzed. (e) Plasma levels of AcSDKP in db/m or db/db mice at euthanasia. in each group were analyzed. The data are expressed as the mean SEM in the figure.

(a)

(b)

(c)

(d)

(e)